TRD
Articles tagged with “TRD”
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
Esketamine's Role in Treatment-Resistant Depression
Esketamine (Spravato) for treatment-resistant depression: how it works, who qualifies, REMS clinic visits, cost ranges, and Spravato vs IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Treatment-Resistant Depression (TRD): Definition, Criteria, and Significance for Ketamine
Treatment-resistant depression (TRD) defined: clinical criteria, the two-failed-trials threshold, and why TRD is the primary indication for ketamine therapy.
Ketamine for Treatment-Resistant Depression
How ketamine therapy is used to treat treatment-resistant depression (TRD), including clinical evidence, response rates, and what patients can expect.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.